ORYZON to present at upcoming international conferences
MADRID, SPAIN and CAMBRIDGE MA.
- Evercore ISI 2nd Annual HealthCONx Conference, Boston, US
- 12th Clinical Trials on Alzheimer’s Disease (CTAD) conference, San Diego, US
- 61st ASH Annual Meeting & Exposition, Orlando, US
- Symposium on 15th anniversary of Histone demethylases, Philadelphia, US
Oryzon Genomics, S.A. (ISIN Code: ES0167733015, ORY), a public clinical-stage biopharmaceutical company leveraging epigenetics to develop therapies in diseases with strong unmet medical needs, announced today that Executive Directors of the company will present at several reputed international conferences in December.